BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31689521)

  • 21. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B; Berenbaum F
    Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial.
    Clouser MC; Roe DJ; Foote JA; Harris RB
    Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):276-83. PubMed ID: 19226541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study.
    Lafrance JP; Miller DR
    Am J Kidney Dis; 2012 Jul; 60(1):82-9. PubMed ID: 22503390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis.
    Yilmaz H; Gürel S; Ozdemir O
    Turk J Gastroenterol; 2005 Sep; 16(3):138-42. PubMed ID: 16245223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee.
    Watson MC; Brookes ST; Kirwan JR; Faulkner A
    Cochrane Database Syst Rev; 2000; (2):CD000142. PubMed ID: 10796306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valdecoxib: a review.
    Chavez ML; DeKorte CJ
    Clin Ther; 2003 Mar; 25(3):817-51. PubMed ID: 12852704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study.
    Arfè A; Scotti L; Varas-Lorenzo C; Nicotra F; Zambon A; Kollhorst B; Schink T; Garbe E; Herings R; Straatman H; Schade R; Villa M; Lucchi S; Valkhoff V; Romio S; Thiessard F; Schuemie M; Pariente A; Sturkenboom M; Corrao G;
    BMJ; 2016 Sep; 354():i4857. PubMed ID: 27682515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Migraine and non-steroidal anti-inflammatory agents].
    Pradalier A; Vincent D
    Pathol Biol (Paris); 1992 Apr; 40(4):397-405. PubMed ID: 1495823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies.
    Varas-Lorenzo C; Riera-Guardia N; Calingaert B; Castellsague J; Salvo F; Nicotra F; Sturkenboom M; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2013 Jun; 22(6):559-70. PubMed ID: 23616423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs).
    Duffy CP; Elliott CJ; O'Connor RA; Heenan MM; Coyle S; Cleary IM; Kavanagh K; Verhaegen S; O'Loughlin CM; NicAmhlaoibh R; Clynes M
    Eur J Cancer; 1998 Jul; 34(8):1250-9. PubMed ID: 9849488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies.
    Martín Arias LH; Martín González A; Sanz Fadrique R; Vazquez ES
    J Clin Pharmacol; 2019 Jan; 59(1):55-73. PubMed ID: 30204233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis.
    Lee C; Hunsche E; Balshaw R; Kong SX; Schnitzer TJ
    Arthritis Rheum; 2005 Aug; 53(4):510-8. PubMed ID: 16082648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
    Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo selectivity of nonsteroidal antiinflammatory drugs and gastrointestinal ulcers in rats.
    Laudanno OM; Cesolari JA; Esnarriaga J; San Miguel P; Bedini OA
    Dig Dis Sci; 2000 Jul; 45(7):1359-65. PubMed ID: 10961715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding.
    Massó González EL; Patrignani P; Tacconelli S; García Rodríguez LA
    Arthritis Rheum; 2010 Jun; 62(6):1592-601. PubMed ID: 20178131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
    McGettigan P; Henry D
    JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study.
    Torti DC; Christensen BC; Storm CA; Fortuny J; Perry AE; Zens MS; Stukel T; Spencer SK; Nelson HH; Karagas MR
    J Am Acad Dermatol; 2011 Aug; 65(2):304-312. PubMed ID: 21529996
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.